Harrow Q3 2022 Earnings Report

Announced third quarter 2022 financial results, highlighting FDA approval for IHEEZO and the launch of Fortisite and atropine.com.

Key Takeaways

Harrow announced its Q3 2022 results, marking an inflection point with FDA approval for IHEEZO, launch of Fortisite, and the sale of its non-ophthalmology compounded product line, focusing the company entirely on the U.S. ophthalmic pharmaceutical market.

Received FDA approval for IHEEZO for ocular surface anesthesia.

Launched Fortisite, a new suite of compounded products.

Sold non-ophthalmology compounded product line to focus on the U.S. ophthalmic pharmaceutical market.

Launched atropine.com to market compounded atropine formulations.

Total Revenue

$22.8M

Previous year: $18.7M

+22.0%

EPS

-$0.06

Previous year: -$0.31

-80.6%